Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 12, 2015, Pages 2171-2180

  Greve, Gabriele ^a,b   Schiffmann, Insa ^a,b   Lübbert, Michael ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c DKTK   (Germany)

Author keywords

Chromatin modification; Epigenetic therapy; Histone acetylation; Non small cell lung cancer; Retinoic acid

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HISTONE H3; PANOBINOSTAT; RETINOIC ACID; ANTINEOPLASTIC AGENT; HISTONE; TUMOR MARKER;

ACETYLATION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; EPIGENETICS; GROWTH INHIBITION; HISTONE ACETYLATION; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; ADENOCARCINOMA; APOPTOSIS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ACETYLATION; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL PROLIFERATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84946480845     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1987-1     Document Type: Article

References (36)

1. Aberle H, Schwartz H, Kemler R (1996) Cadherin–catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 61:514–523. doi:10.1002/(SICI)1097-4644(19960616)61:4<514:AID-JCB4>3.0.CO;2-R
2. Arrieta O, la Rosa CHG-D, Aréchaga-Ocampo E et al (2010) Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3463–3471. doi:10.1200/JCO.2009.26.6452
3. Blagitko-Dorfs N, Jiang Y, Duque-Afonso J et al (2013) Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat. PLoS ONE 8:e75258. doi:10.1371/journal.pone.0075258
4. Brabender J, Metzger R, Salonga D et al (2005) Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis. Carcinogenesis 26:525–530. doi:10.1093/carcin/bgi006
5. Bremnes RM, Veve R, Gabrielson E et al (2002) High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20:2417–2428. doi:10.1200/JCO.2002.08.159
6. Costa DB, Halmos B, Kumar A et al (2007) BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4:e315. doi:10.1371/journal.pmed.0040315
7. Dauphin M, Barbe C, Lemaire S et al (2013) Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer 81:117–122. doi:10.1016/j.lungcan.2013.03.011
8. Degos L (1992) All-trans-retinoic acid treatment and retinoic acid receptor alpha gene rearrangement in acute promyelocytic leukemia: a model for differentiation therapy. Int J Cell Cloning 10:63–69. doi:10.1002/stem.5530100202
9. Dmitriev AA, Kashuba VI, Haraldson K et al (2012) Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics 7:502–513. doi:10.4161/epi.19801
10. Edwards A, Li J, Atadja P et al (2007) Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 6:2515–2524. doi:10.1158/1535-7163.MCT-06-0761
11. Friday BB, Anderson SK, Buckner J et al (2012) Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-Oncol 14:215–221. doi:10.1093/neuonc/nor198
12. Garcia-Manero G, Jabbour E, Borthakur G et al (2013) Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol 31:2548–2553. doi:10.1200/JCO.2012.44.6823
13. Gazdar AF, Carney DN, Russell EK et al (1980) Establishment of continuous, clonable cultures of small-cell carcinoma of the lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 40:3502–3507
14. George P, Bali P, Annavarapu S et al (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105:1768–1776. doi:10.1182/blood-2004-09-3413
15. Grignani F, De Matteis S, Nervi C et al (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815–818. doi:10.1038/35901
16. Guo A, Villen J, Kornhauser J et al (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci 105:692–697. doi:10.1073/pnas.0707270105
17. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
18. Jones DR, Moskaluk CA, Gillenwater HH et al (2012) Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 7:1683–1690. doi:10.1097/JTO.0b013e318267928d
19. Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677. doi:10.1200/JCO.2011.38.9429
20. Lee H-L, Chung T-S, Ting L-L et al (2012) EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 7:181. doi:10.1186/1748-717X-7-181
21. Lieber M, Smith B, Szakal A et al (1976) A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 17:62–70
22. Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121. doi:10.1056/NEJMoa1300874
23. Manna SK, Aggarwal BB (2000) All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappaB, activated protein-1 and apoptosis in human lung cancer cells. Oncogene 19:2110–2119. doi:10.1038/sj.onc.1203547
24. Munker M, Munker R, Saxton RE, Koeffler HP (1987) Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res 47:4081–4085
25. Nouzova M, Holtan N, Oshiro MM et al (2004) Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG Island microarrays. J Pharmacol Exp Ther 311:968–981. doi:10.1124/jpet.104.072488
26. Nowak D, Stewart D, Koeffler HP (2009) Differentiation therapy of leukemia: 3 decades of development. Blood 113:3655–3665. doi:10.1182/blood-2009-01-198911
27. Ohira T, Gemmill RM, Ferguson K et al (2003) WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 100:10429–10434. doi:10.1073/pnas.1734137100
28. Ramalingam SS, Maitland ML, Frankel P et al (2010) Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28:56–62. doi:10.1200/JCO.2009.24.9094
29. Reimer P, Chawla S (2013) Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma. J Hematol Oncol 6:69. doi:10.1186/1756-8722-6-69
30. Renshaw J, Taylor KR, Bishop R et al (2013) Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res 19:5940–5951. doi:10.1158/1078-0432.CCR-13-0850
31. Soltermann A, Tischler V, Arbogast S et al (2008) Prognostic significance of epithelial–mesenchymal and mesenchymal–epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 14:7430–7437. doi:10.1158/1078-0432.CCR-08-0935
32. Tarhini AA, Zahoor H, McLaughlin B et al (2013) Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer Res 33:4475–4481
33. Virmani AK, Fong KM, Kodagoda D et al (1998) Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 21:308–319. doi:10.1002/(SICI)1098-2264(199804)21:4<308:AID-GCC4>3.0.CO;2-2
34. Wang S, Han X, Wang J et al (2014) Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. PLoS ONE 9:e89848. doi:10.1371/journal.pone.0089848
35. Yamashita F, Azuma K, Yoshida T et al (2013) Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PLoS ONE 8:e71356. doi:10.1371/journal.pone.0071356
36. Zhang Z, Lee JC, Lin L et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852–860. doi:10.1038/ng.2330